- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04852705
A Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Adults Aged 18 Years and Older (COVID-19)
April 20, 2021 updated by: Shenzhen Kangtai Biological Products Co., LTD
A Multi-national, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Vaccine (Vero Cells), Inactivated for the Prevention of COVID-19 in Healthy Adults Aged 18 Years and Older
The study will be a multi-national, endpoint-driven, randomized, double-blind, placebo-controlled, adaptive study in which participating adults will be randomized 1:1 to receive 2 doses of either candidate vaccine or placebo on Day 0 and 28.
A total of 28,000 healthy adults aged 18 years and older will be enrolled and followed for efficacy, safety, and immunogenicity evaluations.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
28000
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Guifan Li, M.S
- Phone Number: +861059613591
- Email: liguifan@biominhai.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy residents ≥ 18 years at the time of consent, be voluntary and capable of signing the informed consent forms.
- Be able to understand and comply with study requirements/ procedures.
- Participants with negative results of SARS-CoV-2 Realtime-PCR (RT-PCR) detection.
- For females or sex-partners of males at childbearing age: be willing to use birth control for 3 months after the 2nd dose.
- For females of childbearing potential (Pausimenia ≤ 2 years ) must: have a negative urine or blood pregnancy test at screening
- Axillary temperature < 37.3℃/99.1℉ when screening (Subsequent measurements of temperature should be performed at the same site per participant; temperature measured by other methods should be converted to axillary temperature ).
Exclusion Criteria:
- Previous treatments for curing or preventing COVID-19 (including vaccination of various COVID-19 vaccines).
- History of Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS) or other coronavirus infections.
- History of allergy to any components of the candidate vaccine or severe allergic reactions to vaccine or medicine (including, but not limited to, allergic shock, allergic laryngeal edema, allergic purpura, thrombocytopenic purpura, or local allergic necrosis (Arthus reaction)).
- Positive for HIV detection.
- History or family history of convulsion, epilepsy, encephalopathy, and psychosis.
- Active stage of malignancies, malignancies without adequate treatments, malignancies with potential risk for recurrence during the study.
- Severe or uncontrolled cardiovascular, neurological, blood and lymphatic, kidney, liver, respiratory, metabolic and skeletal diseases.
- Congenital or functional absence of spleen, complete or partial removal of spleen in any case.
- Chronic administration (defined as ≥ 14 days) of immunosuppressants or other immune-modifying drugs within 6 months prior to the 1st vaccination (eg. corticosteroids, ≥ 0.5 mg/kg/day prednisone or equivalent; but, inhaled and topical steroids are allowed).
- Planned administration/administration of a vaccine not foreseen by the study protocol less than 7 days before 1st dose of candidate vaccine for inactivated vaccines or 14 days before 1st dose of candidate vaccine for attenuated live vaccines.
- Receipt of blood products and/or immunoglobulins within 3 months prior to enrollment or expected receipt during the study.
- Donate or loss ≥ 450 ml of blood within 1 month prior to enrollment, or expected blood donation during the study.
- Fever: axillary temperature ≥ 37.3℃/99.1℉ within the past 24 hours (Subsequent measurements of temperature should be performed at the same site per participant; temperature measured by other methods should be converted to axillary temperature ).
- Those who participated in other clinical trials 1 month prior to the enrollment or used any investigational or non-registered drug during the study period; Those who are unable to finish follow-up or fail in efficacy assessments.
- Breastfeeding females should not be included.
- Ineligible for the study based on the assessment of investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
2 doses of Placebo should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.
|
Experimental: candidate vaccine
|
2 doses of SARS-CoV-2 Vaccine (Vero Cells), Inactivated should be administered as an intramuscular injection into the lateral deltoid of the upper arm with a 28-day interval.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence density of symptomatic COVID-19 cases
Time Frame: 14 days after full vaccination
|
Incidence density of symptomatic COVID-19 cases occurring from 14 days after full vaccination.
|
14 days after full vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence density of COVID-19 moderate cases and above
Time Frame: 14 days after full vaccination
|
Incidence density of COVID-19 moderate cases and above occurring from 14 days after full vaccination.
|
14 days after full vaccination
|
Incidence density of COVID-19 severe cases and above
Time Frame: 14 days after full vaccination
|
Incidence density of COVID-19 severe cases and above occurring from 14 days after full vaccination.
|
14 days after full vaccination
|
Incidence density of COVID-19 death cases and above
Time Frame: 14 days after full vaccination
|
Incidence density of COVID-19 death cases and above occurring from 14 days after full vaccination.
|
14 days after full vaccination
|
Incidence density of symptomatic COVID-19 cases in different age groups
Time Frame: 14 days after full vaccination
|
Incidence density of symptomatic COVID-19 cases occurring from 14 days after full vaccination in different age groups (18~59 years and ≥ 60 years).
|
14 days after full vaccination
|
Incidence of solicited local adverse events
Time Frame: 0-7 days after each vaccination
|
Incidence of solicited local adverse events occurring 0-7 days after each vaccination.
|
0-7 days after each vaccination
|
Incidence of solicited general adverse events
Time Frame: 0-7 days after each vaccination
|
Incidence of solicited general adverse events occurring 0-7 days after each vaccination.
|
0-7 days after each vaccination
|
Incidence of unsolicited adverse events
Time Frame: 0-28 days after each vaccination
|
Incidence of unsolicited adverse events occurring 0-28 days after each vaccination.
|
0-28 days after each vaccination
|
Incidence of SAE
Time Frame: from the 1st dose through the end of study
|
Incidence of SAE occurring from the 1st dose through the end of study.
|
from the 1st dose through the end of study
|
Incidence of AESI
Time Frame: from the 1st dose through the end of study
|
Incidence of AESI occurring from the 1st dose through the end of study.
|
from the 1st dose through the end of study
|
Seroconversion rate of SARS-CoV-2 neutralizing antibody
Time Frame: 28 days, 90 days, 180 days and 360 days after full vaccination
|
Seroconversion rate of SARS-CoV-2 neutralizing antibody in the immunogenicity subgroup
|
28 days, 90 days, 180 days and 360 days after full vaccination
|
Geometric mean titer of SARS-CoV-2 neutralizing antibody
Time Frame: 28 days, 90 days, 180 days and 360 days after full vaccination
|
geometric mean titer of SARS-CoV-2 neutralizing antibody in the immunogenicity subgroup
|
28 days, 90 days, 180 days and 360 days after full vaccination
|
Geometric mean fold increase of SARS-CoV-2 neutralizing antibody
Time Frame: 28 days, 90 days, 180 days and 360 days after full vaccination
|
Geometric mean fold increase of SARS-CoV-2 neutralizing antibody in the immunogenicity subgroup
|
28 days, 90 days, 180 days and 360 days after full vaccination
|
Seroconversion rate of SARS-CoV-2 IgG binding antibody
Time Frame: 28 days, 90 days, 180 days and 360 days after full vaccination
|
Seroconversion rate of SARS-CoV-2 IgG binding antibody in the immunogenicity subgroup
|
28 days, 90 days, 180 days and 360 days after full vaccination
|
Geometric mean titer of SARS-CoV-2 IgG binding antibody
Time Frame: 28 days, 90 days, 180 days and 360 days after full vaccination
|
Geometric mean titer of SARS-CoV-2 IgG binding antibody in the immunogenicity subgroup
|
28 days, 90 days, 180 days and 360 days after full vaccination
|
Geometric mean fold increase of SARS-CoV-2 IgG binding antibody
Time Frame: 28 days, 90 days, 180 days and 360 days after full vaccination
|
Geometric mean fold increase of SARS-CoV-2 IgG binding antibody in the immunogenicity subgroup
|
28 days, 90 days, 180 days and 360 days after full vaccination
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
May 1, 2021
Primary Completion (Anticipated)
November 1, 2021
Study Completion (Anticipated)
November 1, 2022
Study Registration Dates
First Submitted
April 20, 2021
First Submitted That Met QC Criteria
April 20, 2021
First Posted (Actual)
April 21, 2021
Study Record Updates
Last Update Posted (Actual)
April 22, 2021
Last Update Submitted That Met QC Criteria
April 20, 2021
Last Verified
April 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2021L001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on SARS-CoV-2 Vaccine (Vero Cells), Inactivated
-
Shenzhen Kangtai Biological Products Co., LTDBeijing Minhai Biotechnology Co., Ltd; Hunan Provincial Center for Disease...Not yet recruiting
-
Shenzhen Kangtai Biological Products Co., LTDBeijing Minhai Biotechnology Co., Ltd; Hunan Provincial Center for Disease...Not yet recruiting
-
Sinovac Research and Development Co., Ltd.Active, not recruiting
-
Ruijin HospitalRecruitingCovid19 | SARS-CoV-2 InfectionChina
-
China National Biotec Group Company LimitedBeijing Institute of Biological Products Co Ltd.CompletedCOVID-19 | COVID-19 PneumoniaUnited Arab Emirates
-
Cancer Institute and Hospital, Chinese Academy...Hubei Provincial Center for Disease Control and PreventionRecruiting
-
Cancer Institute and Hospital, Chinese Academy...Yunnan Center for Disease Control and PreventionRecruiting
-
Cancer Institute and Hospital, Chinese Academy...Yunnan Center for Disease Control and PreventionRecruiting
-
PT. Kimia Farma (Persero) TbkActive, not recruiting
-
Cancer Institute and Hospital, Chinese Academy...Enrolling by invitation